BioCorRx

BioCorRx CROIC

The Cash Return on Invested Capital (CROIC) of BioCorRx (BICX) as of Oct 5, 2026 is 20.61 %. In the previous year, Cash Return on Invested Capital (CROIC) was 9.10 % — a change of 126.48% (higher).

CROIC

20.61 %

YoY

126.48%

Last updated:

Cash Return on Invested Capital (CROIC) of BioCorRx is 2026 20.61 % . Cash Return on Invested Capital (CROIC) of BioCorRx was 2025 9.10 % . It decreases by 126.48% higher compared to the previous year.

The BioCorRx CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
138.18 USD
Jan 1, 2019
409.44 USD
Jan 1, 2020
52.68 USD
Jan 1, 2021
52.15 USD
Jan 1, 2022
25.51 USD
Jan 1, 2023
19.01 USD
Jan 1, 2024
9.10 USD
Jan 1, 2025
20.61 USD
The BioCorRx CROIC history
YEARCROICYoY
20.61 %+126.48%
9.10 %-52.13%
19.01 %-25.51%
25.51 %-51.08%
52.15 %-1.01%
52.68 %-87.13%
409.44 %+196.30%
138.18 %-8.17%
150.47 %+350.63%
33.39 %-2,246.75%
-1.56 %-108.69%
17.90 %—
Access this data via the Eulerpool API

BioCorRx Stock analysis

What does BioCorRx do? The company BioCorRx Inc is a US-American company that was founded in 2008 and is headquartered in Anaheim, California. BioCorRx specializes in the development and marketing of innovative treatment methods for alcohol and drug dependency. The history of BioCorRx began with the introduction of its flagship product, the BioCorRx Recovery Program, which is based on a novel medical technology called Naltrexone/Buprenorphine Implant. Unlike traditional methods of treating alcohol and drug addiction, which typically rely on medication and psychotherapeutic support, the BioCorRx Recovery Program is an implantable, long-term treatment system that continuously delivers the active ingredient Naltrexone or Buprenorphine into the patient's body. The idea behind this is that the active ingredients prevent withdrawal symptoms and thereby reduce the risk of relapse. In recent years, BioCorRx has expanded its product portfolio and expanded its business activities to new segments in order to further drive the company's growth. This includes, for example, the field of telemedicine services, which allow BioCorRx to offer its treatment technology and medical services through online communication. Telemedicine services such as virtual patient consultation or online group therapy programs are particularly in demand in times of COVID-19. Another focus of BioCorRx is the management of medical personnel. Studies have shown that good patient care and counseling heavily influence the success of treatment. BioCorRx has now also developed its own platform that eases and improves the management, training, and monitoring of medical staff. BioCorRx also utilizes the concept of franchise systems to market its products and services. The franchise system offers medical professionals and organizations working in the field of addiction treatment the opportunity to open their own BioCorRx clinic and offer the company's products and services in their local market. Each clinic is advised and supported by BioCorRx and must adhere to certain standards and quality criteria. In the future, BioCorRx plans to further diversify its product offering and develop new technologies to improve treatment options for alcohol and drug dependents. An example of such a technology is medication based on Ibogaine. BioCorRx has already started initial research in this direction and is actively working on pre-clinical studies. Overall, BioCorRx is a company that primarily focuses on innovative technologies for the treatment of addiction. The company has experienced substantial growth in recent years by expanding its product range and customer base, and focusing on the areas of telemedicine, personnel management, and franchise systems. With its forward-thinking technologies and strong emphasis on quality and patient satisfaction, BioCorRx is expected to continue playing an important role in addiction treatment in the years to come. BioCorRx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioCorRx stock

Cash Return on Invested Capital (CROIC) of BioCorRx is 20.61 % in 2026.

Cash Return on Invested Capital (CROIC) of BioCorRx changed from 9.10 % to 20.61 %, representing a 126.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) BioCorRx since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s BioCorRx with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

Profitability — BioCorRx

All Key Metrics — BioCorRx